Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer.
OBJECTIVE
To report regression of corneal stromal neovascularizations with the use of topical cyclosporine 0.05% in a corneal transplant patient performed for fungal corneal ulcer.


METHODS
Case report.


METHODS
A 14-year-old boy treated for fungal corneal ulceration developed 360 degrees corneal stromal neovascularization peroperatively. Topical cyclosporine 0.05% was used to decrease the risk of rejection.


RESULTS
The neovascularizations regressed totally within 2 months and no signs of graft rejection were present at 6 months follow up.


CONCLUSIONS
Topical cyclosporine 0.05% may result in regression of stromal corneal neovascularizations and help to reduce the risk of graft rejection in selected cases.
Sonmez
Baris
B
Department of Ophthalmology, Ondokuzmayis University, Samsun, Turkey. drbarissonmez@gmail.com
Beden
Umit
U
Erkan
Dilek
D
D000287:Administration, Topical; D000293:Adolescent; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D003319:Corneal Stroma / Q000098:blood supply; D003320:Corneal Ulcer / Q000382:microbiology* / Q000628:therapy*; D016572:Cyclosporine / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015948:Keratoplasty, Penetrating / Q000009:adverse effects; D008297:Male; D009181:Mycoses / Q000150:complications* / Q000628:therapy*; D011182:Postoperative Care; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine